We Can Medicines (6929) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 佑全

We Can Medicines (6929) reported revenue of NT$284 million for Oct 2026, +4.5% year on year and +6.6% from the previous month. Revenue for Jan–Oct 2026 was NT$2.7 billion (+0.7% year on year).

Year-on-year revenue growth: 4 months in a row. →

In Oct 2026, it ranked No. 34 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$263.5 million24/10Nov 2024 NT$271.8 millionDec 2024 NT$279.3 millionJan 2025 NT$282.1 millionFeb 2025 NT$250.5 million25/02Mar 2025 NT$265.3 millionApr 2025 NT$264.4 millionMay 2025 NT$283.4 millionJun 2025 NT$269.1 million25/06Jul 2025 NT$266.5 millionAug 2025 NT$269.9 millionSep 2025 NT$253.2 millionOct 2025 NT$271.9 million25/10Nov 2025 NT$273.6 millionDec 2025 NT$272.1 millionJan 2026 NT$264.8 millionFeb 2026 NT$260 million26/02Mar 2026 NT$272 millionApr 2026 NT$262.3 millionMay 2026 NT$282.9 millionJun 2026 NT$257.4 million26/06Jul 2026 NT$270 millionAug 2026 NT$275.4 millionSep 2026 NT$266.4 millionOct 2026 NT$284 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$284 million+4.5%+6.6%
Sep 2026NT$266.4 million+5.2%-3.2%
Aug 2026NT$275.4 million+2.0%+2.0%
Jul 2026NT$270 million+1.3%+4.9%
Jun 2026NT$257.4 million-4.3%-9.0%
May 2026NT$282.9 million-0.2%+7.8%
Apr 2026NT$262.3 million-0.8%-3.6%
Mar 2026NT$272 million+2.5%+4.6%
Feb 2026NT$260 million+3.8%-1.8%
Jan 2026NT$264.8 million-6.1%-2.7%
Dec 2025NT$272.1 million-2.6%-0.6%
Nov 2025NT$273.6 million+0.7%+0.6%
Oct 2025NT$271.9 million+3.2%+7.4%
Sep 2025NT$253.2 million-6.4%-6.2%
Aug 2025NT$269.9 million-1.6%+1.3%
Jul 2025NT$266.5 million-0.5%-1.0%
Jun 2025NT$269.1 million+0.6%-5.0%
May 2025NT$283.4 million+4.9%+7.2%
Apr 2025NT$264.4 million-7.6%-0.3%
Mar 2025NT$265.3 million-2.4%+5.9%
Feb 2025NT$250.5 million-6.2%-11.2%
Jan 2025NT$282.1 million+1.0%+1.0%
Dec 2024NT$279.3 million+2.1%+2.8%
Nov 2024NT$271.8 million+2.4%+3.1%
Oct 2024NT$263.5 million-3.6%-2.6%

Jan–Oct 2026 cumulative: NT$2.7 billion (+0.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: We Can Medicines vs PEC / We Can Medicines vs Lotus Pharm / We Can Medicines vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16